MedTrace Logo

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

NCT02282605 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-10-07

Study results available
· View outcomes & findings →

Summary

Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus aureus.

Conditions

  • Staphylococcus Aureus Infection

Interventions

DRUG

XF-73 nasal gel

DRUG

Placebo nasal gel

OTHER

Chlorhexidine gluconate 2% topical cloths

Sponsors & Collaborators

  • Destiny Pharma Plc

    lead INDUSTRY

Principal Investigators

  • Ian Mr Hayter, BSc · Destiny Pharma Plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282605 on ClinicalTrials.gov